Get the Stockscreener App
325.11
0.88%
-2.2027
Madrigal Pharmaceuticals Inc stock is traded at $325.11, with a volume of 19,878.
It is down -0.88% in the last 24 hours and down -7.76% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$327.31
Open:
$325.99
24h Volume:
19,878
Relative Volume:
0.05
Market Cap:
$7.17B
Revenue:
-
Net Income/Loss:
$-518.67M
P/E Ratio:
-12.94
EPS:
-25.12
Net Cash Flow:
$-438.32M
1W Performance:
-1.32%
1M Performance:
-7.76%
6M Performance:
+34.17%
1Y Performance:
+18.85%
1-Day Range:
$323.01
$327.86
1-Week Range:
$315.02
$344.17
52-Week Range:
$189.00
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
325.10 | 7.17B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.30 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.83 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.42 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.49 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.97 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal Pharmaceuticals Announces Changes to Board of Directors - MyChesCo
Madrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potential - Investing.com India
Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 - Investing.com
Madrigal Pharmaceuticals SVP and CFO sells stock for $83,344 By Investing.com - Investing.com UK
Victory Capital Management Inc. Has $21.80 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Bank of New York Mellon Corp Lowers Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
How the (MDGL) price action is used to our Advantage - Stock Traders Daily
Madrigal Pharmaceuticals Expands Board with New Appointment - TipRanks
Madrigal appoints Jacqualyn Fouse to its board -March 11, 2025 at 09:36 am EDT - Marketscreener.com
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. To Board - citybiz
Madrigal Pharmaceuticals appoints new board member - Investing.com India
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors - The Manila Times
Why Madrigal Pharmaceuticals (MDGL) Stock is Rising Today - GuruFocus.com
Robert E. Waltermire Sells 14,113 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - Defense World
Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, - GuruFocus.com
Madrigal Pharmaceuticals Exec Cashes Out in Multi-Million Dollar Stock Sale! - TipRanks
Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock By Investing.com - Investing.com Canada
Madrigal Pharmaceuticals’ senior VP sells $4.8 million in stock - Investing.com India
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Holdings Reduced by Principal Financial Group Inc. - Defense World
Madrigal Pharmaceuticals CFO Mardi sells $637,247 in stock - Investing.com India
Madrigal Pharmaceuticals exec sells $418,488 in stock By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals exec sells $418,488 in stock - Investing.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% on Insider Selling - Defense World
B. Riley Analysts Increase Earnings Estimates for MDGL - Defense World
Sanctuary Advisors LLC Acquires 62 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
HC Wainwright Issues Negative Estimate for MDGL Earnings - Defense World
Madrigal Pharmaceuticals Reports Strong 2024 Growth Fueled by Rezdiffra Launch - MSN
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $351.67 Consensus PT from Analysts - MarketBeat
New York State Common Retirement Fund Sells 5,630 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat
Citigroup Boosts Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $469.00 - Defense World
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Madrigal Pharmaceuticals director Kenneth Bate sells $7.1m in stock By Investing.com - Investing.com Australia
(MDGL) Trading Report - Stock Traders Daily
Madrigal Pharmaceuticals director Kenneth Bate sells $7.1m in stock - Investing.com
Citigroup Issues Positive Forecast for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price - MarketBeat
Madrigal Pharmaceuticals: Rezdiffra First-Mover Advantage Gains Traction (Upgrade) (MDGL) - Seeking Alpha
Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA - Yahoo Finance
Madrigal Pharmaceuticals (NASDAQ:MDGL) Given New $405.00 Price Target at HC Wainwright - MarketBeat
B. Riley Upgrades Madrigal Pharmaceuticals to Buy From Neutral, Raises Price Target to $422 From $236 - Marketscreener.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up After Strong Earnings - Defense World
Madrigal’s Earnings Call Highlights Strong Growth - TipRanks
Madrigal Pharmaceuticals price target raised to $443 from $427 at Citizens JMP - TipRanks
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture? - Benzinga India
Madrigal Pharmaceuticals (NASDAQ:MDGL) Releases Quarterly Earnings Results, Beats Estimates By $1.61 EPS - MarketBeat
Madrigal Pharmaceuticals Shares Still Undervalued Amid Long-Term Growth Potential, UBS Says - Marketscreener.com
UBS maintains Buy on Madrigal Pharmaceuticals, target at $441 - Investing.com India
UBS maintains Buy on Madrigal Pharmaceuticals, target at $441 By Investing.com - Investing.com UK
Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley - TipRanks
Madrigal Pharmaceuticals Inc (MDGL) Q4 2024 Earnings Call Highli - GuruFocus.com
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Call Transcript - Insider Monkey
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):